<DOC>
	<DOCNO>NCT00772681</DOCNO>
	<brief_summary>- To assess efficacy docetaxel , cisplatin combination term disease free survival . - Time progression disease term local distant failure ; ass survival time , assess objective ( clinical radiological ) response rate safety treatment .</brief_summary>
	<brief_title>Efficacy Chemoradiotherapy After Neoadjuvant Cisplatin Docetaxel Nasopharynx Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically/cytologically confirm , patient stage T2bT4N1 TanyN23 undifferentiated nonkeratinized squamous cell carcinoma nasopharynx candidate curative radiotherapy . ECOG Performance Status 01 Weight loss within last 6 month &lt; 10 % body weight Acceptable haematological profile ( define leukocyte count ≥ 4000/mm3 , platelet count ≥ 100.000mm3 Hb ≥ 9g/100mL ) , adequate renal function ( define serum creatinine ≤ 1.5mg/dl ) , hepatic function ( define bilirubin ≤ 1.5 x maximum normal value even hepatic metastasis ; transaminase ( ALT , AST ) ≤ 1.5 x maximum normal value ; alkaline phosphatase ≤ 2.5 x maximum normal value , except case bone metastasis ) Patients stage IVC metastatic disease Patients treat chemotherapy nasopharyngeal cancer Patients treat radiotherapy head neck region Concomitant use another anticancer therapy Patients treat amifostine pilocarpine protocol treatment . Unstable medical condition make patient unable take part clinical study ( congestive heart failure , serious arrhythmia , uncontrolled diabetes mellitus ) , history myocardial infarction within last 6 month , massive pleural , peritoneal pericardial effusion ; presence serious uncontrolled infection . Presence tumours different carcinoma skin except melanoma carcinoma situ breast cervix disease free survival le 5 year . Pregnancy breastfeed . In woman childbearing potential men , adequate contraceptive method must use Social psychological condition render patient inadequate followup study Contraindication study drug ( e.g . history hypersensitivity ingredient study drug ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>